• Users Online: 548
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2012  |  Volume : 37  |  Issue : 4  |  Page : 252-256

Role of P53 deletion in patients with acute myeloid leukaemia

1 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Mona A. Ismail
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7123/01.EJH.0000419282.79533.ff

Rights and Permissions


Loss of the P53 tumour suppressor gene located on the short arm of chromosome 17 (17p13.1) is frequently associated with aggressive disease courses and drug resistance. The prognostic association of P53 deletion has been confirmed for chronic myeloid leukaemia, but not for acute myeloid leukaemia (AML).

Aim of work

The aim of the current study was to investigate the prognostic value of P53 deletion in de-novo patients with AML and to correlate this with known prognostic parameters as well as clinical outcome.

Patients and methods

This study was conducted on 91 patients with de-novo AML meeting WHO criteria for AML. The fluorescence in-situ hybridization technique was applied for detection of P53 deletion at the time of diagnosis. Follow-up studies were carried out to evaluate therapeutic response and clinical outcome.


Loss of P53 was detected in eight out of 91 (8.8%) patients with AML. Among them seven (87.5%) had complex aberrations. A significant difference was detected between P53 deletion positive and negative patients as regards age and total leukocyte count. A highly significant association was detected between P53 deletion and incomplete remission. Interestingly, the coexistence of P53 deletion with old age and high total leukocyte count exhibited a negative impact on the outcome in patients.


P53 deletion can be considered as an indicator of poor therapeutic response in AML patients. Developing new drugs targeting the P53 pathway could be a way to improve treatment of AML.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded116    
    Comments [Add]    

Recommend this journal